Silvia Gobbi

TL;DR: A series of hybrid compounds structurally derived from donepezil and AP2238, with a 5-carbon alkyl chain bearing an amino moiety at one end, better contacting the PAS, remarkably improved the inhibition of AChE-induced Abeta aggregation with respect to the reference compounds.

TL;DR: This review accounts for small-molecule inhibitors of Aβ peptide polymerization and toxicity, reported in the patent literature during the 2010 – 2012 period, and their potential use as disease-modifying therapeutics for AD cure.

TL;DR: A focused collection of new 2-arylbenzofurans were designed and synthesized and evaluated their biological properties towards specific targets involved in AD, namely human AChE and human BuChE, and Aβ fibril formation and 1 showed good selectivity and moderate affinity for CB1 receptor.

TL;DR: This review summarizes the progresses that have been made in the design of hybrid molecules for the treatment of AD by identifying novel AChEIs that were able to hit a number of specific AD targets and proved to possess antioxidant, anti-inflammatory, or neuroprotective activities, useful to block or revert the progression of the disease.

TL;DR: A new series of molecules was designed and synthesized, exploring possible structural modifications of a previously identified xanthone scaffold, and highly potent compounds, with inhibitory activity in the low nanomolar range were found.